Estimated annual savings to consumers are put at ₹3,502.31 crore as revised prices take effect today.
The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins on the MRP of 137 anti-cancer drugs, based on the recommendations of an Expert Committee constituted by the Directorate General of Health Services (DGHS) under the Ministry of Health & Family Welfare. The revised prices of these drugs come into effect from today.
As of now, 76 pharmaceutical companies have reported revised MRP for 1,225 anti-cancer formulations, covering 121 drugs. Reductions have been reported in 1,031 formulations, with 600 brands reporting a reduction of more than 50% and the highest reduction at 96.45%.
Of the 137 identified drugs, 10 to 15 are yet to be launched in India. Trade Margin Rationalization (TMR) will apply to these drugs as and when they are launched.
As a result of the price reductions, the estimated annual savings to consumers would be ₹3,502.31 crore. TMR of non-scheduled anti-cancer medicines is an important step taken by the Government to improve affordability and accessibility of essential anti-cancer medicines for cancer care.
Source: Akashvani News
